New – About Us

Tivic Health. We are an immunotherapeutics company.
Tivic seeks to treat unmet medical needs with a dual platform approach to targeting the immune system. Tivic’s dual platform comprises biopharmaceutical treatments and a bioelectronic treatment, (i.e., a non-invasive vagus nerve stimulation device).
Tivic’s biologic compounds activate an innate immune pathway to prevent cell death in the bone marrow and the epithelial tissues across systems impacted by radiation and age.
The company’s lead drug candidate, Entolimod™ for acute radiation syndrome, or ARS, is a novel TLR5 agonist that has been granted Fast Track and Orphan Drug designation and is in late-stage development.
Tivic’s bioelectronic program has under development a novel, non-invasive medical device designed to target the neural pathways implicated in many prevalent and debilitating diseases.
Early device trials show promising signals for regulating specific biologic responses.
Tivic believes its early-stage vagus nerve stimulation device has the potential to deliver clinical outcomes similar to or better than those of surgically implanted devices, but without the side effects or risks inherent in invasive surgical implants.
Awards & Recognition
Tivic Health and ClearUP have earned accolades and awards from around the globe.
